Fallout From This Heart-Drug Failure
Big biotech Amgen and its partner Cytokinetics had an intriguing drug candidate -- omecamtiv mecarbill, which treats shortness of breath in patients with acute heart failure -- fail a mid-stage trial. Amgen wasn't affected, but shares of Cytokinetics plunged 25% on the news.
There is a caveat to this failure: It was at the lower dosing, and most analysts didn't expect the trial to succeed. The higher dosing did show efficacy, but when the data was pooled, the results became muddled.
In this video, health-care analyst David Williamson discusses whether the heart-failure drug will reach phase 3 testing and looks at whether Cytokinetics or Amgen is the better play for investors.
Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
The article Fallout From This Heart-Drug Failure originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.